4-(4-氯苯基)苄基胺盐酸盐 | 410077-96-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(4-氯苯基)苄基胺盐酸盐
• 中文别名: [4-(4-氯苯基)苯基]甲胺盐酸盐；[4-(4-氯苯基)苯基]甲基胺盐酸盐
• 英文名称: (4′-chlorobiphenyl-4-yl)methylammonium chloride
• 英文别名: (4'-chlorobiphenyl-4-yl)methylamine hydrochloride；p-(p-chlorophenyl)benzylamine hydrochloride；[4-(4-Chlorophenyl)phenyl]methylamine hydrochloride；[4-(4-chlorophenyl)phenyl]methanamine;hydrochloride
• CAS: 410077-96-2
• 化学式: C₁₃H₁₂ClN*ClH
• 分子量: 254.159
• InChiKey: PUSWBWIRYUMVRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.89
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  4-(4-氯苯基)苄基胺盐酸盐 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 [4-(4-氯苯基)苯基]甲胺
  参考文献：
  名称：

  Substituted N-(Biphenyl-4′-yl)methyl (R)-2-Acetamido-3-methoxypropionamides: Potent Anticonvulsants That Affect Frequency (Use) Dependence and Slow Inactivation of Sodium Channels

  摘要：

  We prepared 13 derivatives of N-(biphenyl-4'-yl)methyl (R)-2-acetamido-3-methoxypropionamide that differed in type and placement of a R-substituent in the terminal aryl unit. We demonstrated that the R-substituent impacted the compound's whole animal and cellular pharmacological activities. In rodents, select compounds exhibited excellent anticonvulsant activities and protective indices (PI = TD50/ED50) that compared favorably with clinical antiseizure drugs. Compounds with a polar, aprotic R-substituent potently promoted Na+ channel slow inactivation and displayed frequency (use) inhibition of Na+ currents at low micromolar concentrations. The possible advantage of affecting these two pathways to decrease neurological hyperexcitability is discussed.

  DOI：

  10.1021/jm500707r
• 作为产物：
  描述：

  [4-(4-氯苯基)苯基]甲胺 在 盐酸 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 1.0h， 以1 g的产率得到4-(4-氯苯基)苄基胺盐酸盐
  参考文献：
  名称：

  (Biphenyl-4-yl)methylammonium Chlorides: Potent Anticonvulsants That Modulate Na⁺ Currents

  摘要：

  We have reported that compounds containing a biaryl linked unit (Ar-X-Ar') modulated Na+ currents by promoting slow inactivation and fast inactivation processes and by inducing frequency (use)-dependent inhibition of Na+ currents. These electrophysiological properties have been drugs. In this study, we demonstrate that the readily accessible associated with the mode of action of several antiepileptic (biphenyl-4-yl)methylammonium chlorides (compound class B) exhibited a broad range of anticonvulsant activities in animal models, and in the maximal electroshock seizure test the activity of (3'-trifluoromethoxybiphenyl-4-yl)methylammonium chloride (8) exceeded that of phenobarbital and phenytoin upon oral administration to rats. Electrophysiological studies of 8 using mouse catecholamine A-differentiated cells and rat embryonic cortical neurons confirmed that 8 promoted slow and fast inactivation in both cell types but did not affect the frequency (use)-dependent block of Na+ currents.

  DOI：

  10.1021/jm4007092

文献信息

• Synthesis and Mode of Action of Hydrophobic Derivatives of the Glycopeptide Antibiotic Eremomycin and Des-(<i>N</i>-methyl-<scp>d</scp>-leucyl)eremomycin against Glycopeptide-Sensitive and -Resistant Bacteria
  作者：Svetlana S. Printsevskaya、Andrey Y. Pavlov、Evgenia N. Olsufyeva、Elena P. Mirchink、Elena B. Isakova、Marina I. Reznikova、Robert C. Goldman、Arthur A. Branstrom、Eugene R. Baizman、Clifford B. Longley、Ferenc Sztaricskai、Gyula Batta、Maria N. Preobrazhenskaya

  DOI：10.1021/jm010460i

  日期：2002.3.1

  was obtained by Edman degradation of eremomycin. Derivatives with a hydrophobic substituent at the exterior of the molecule were then synthesized, and their antibacterial activities were compared with similar derivatives of eremomycin. Comparison of derivatives of eremomycin containing the n-decyl or p-(p-chlorophenyl)benzyl substituent in the eremosamine moiety (N') and n-decyl or p-(p-chlorophenyl)benzylamides

  Des-（N-甲基-D-亮氨酰）eremomycin是通过Edman降解ememomycin获得的。然后合成在分子外部具有疏水取代基的衍生物，并将其抗菌活性与埃雷霉素的类似衍生物进行比较。比较埃雷莫胺部分（N'）中含有正癸基或对-（对氯苯基）苄基的埃雷霉素衍生物和正癸基或对-（对氯苯基）苄基酰胺与具有受损肽的埃雷霉素类似衍生物的比较核心（有缺陷的结合口袋）表明，这两种类型的化合物对肠球菌（GRE）的糖肽耐药菌株几乎具有相同的活性，而埃雷霉素衍生物对葡萄球菌的活性更高。埃雷霉素的疏水7d-烷基氨基甲基化衍生物（9，10）表现出相似的抗菌性能。由于糖肽类抗生素的基本作用方式涉及与终止于-D-Ala-D-Ala的细胞壁中间体的结合，并且六肽衍生物中的这种相互作用被严重降低（缺乏关键的N-甲基-D-亮氨酸），我们建议这些疏水性衍生物可以在不存在二肽结合的情况下抑制肽聚糖的合成。使用Ac-D-Ala
• Novel Cyclic Amino Benzoic Acid Derivative
  申请人：Nomura Masahiro

  公开号：US20070249580A1

  公开（公告）日：2007-10-25

  The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARα isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. A cyclic amino benzoic acid derivative represented by the general formula (1) [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C 1 -C 4 alkylene, C 2 -C 4 alkenylene, C 2 -C 4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or —(CH 2 ) n — (n represents 0, 1 or 2); X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, or the like; R represents a hydrogen atom or lower alkyl group, and —COOR substitutes for an ortho position or metha position of binding position of ring W] or a pharmaceutically acceptable salt thereof.

  本发明涉及循环氨基苯甲酸衍生物，作为人类过氧化物酶体增殖物激活受体（PPAR）激动剂，在治疗脂质代谢异常、糖尿病等方面具有有效性，特别是作为人类PPARα亚型的激动剂，以及其加成盐和含有这些化合物的药物组合物。其中，循环氨基苯甲酸衍生物的一般式（1）表示为[其中，环Ar表示可能具有取代基的芳基；Y表示C1-C4烷基、C2-C4烯基、C2-C4炔基或类似物；Z表示氧原子、硫原子或—（CH2）n—（n表示0、1或2）；X表示氢原子、卤原子、可能带有卤原子取代的低烷基或类似物；R表示氢原子或低烷基，而—COOR代替环W的结合位置的邻位或间位]或其药学上可接受的盐。
• Cyclic amino benzoic acid derivative
  申请人：Kyorin Pharmaceutical Co., Ltd.

  公开号：US07902367B2

  公开（公告）日：2011-03-08

  The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARα isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. A cyclic amino benzoic acid derivative represented by the general formula (1) [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C1-C4 alkylene, C2-C4 alkenylene, C2-C4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or —(CH2)n— (n represents 0, 1 or 2); X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, or the like; R represents a hydrogen atom or lower alkyl group, and —COOR substitutes for an ortho position or metha position of binding position of ring W] or a pharmaceutically acceptable salt thereof.

  本发明涉及循环氨基苯甲酸衍生物，其作为人类过氧化物酶体增殖物激活受体（PPAR）激动剂在治疗脂质代谢异常、糖尿病等方面具有有效性，特别是作为人类PPARα亚型的激动剂，以及其加成盐和含有这些化合物的制药组合物。其中循环氨基苯甲酸衍生物的一般式（1）表示为[其中环Ar表示可能具有取代基的芳基基团或类似物；Y表示C1-C4烷基，C2-C4烯基，C2-C4炔基或类似物；Z表示氧原子、硫原子或—（CH2）n—（n表示0、1或2）；X表示氢原子、卤原子、可能被卤原子取代的低烷基基团或类似物；R表示氢原子或低烷基基团，而—COOR代替环W的连接位置的邻位或甲位]或其药学上可接受的盐。
• NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE
  申请人：KYORIN PHARMACEUTICAL CO., LTD.

  公开号：EP1780210A1

  公开（公告）日：2007-05-02

  The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARα isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. A cyclic amino benzoic acid derivative represented by the general formula (1) [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C1-C4 alkylene, C2-C4 alkenylene, C2-C4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or - (CH2)n- (n represents 0,1 or 2) ; X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, or the like; R represents a hydrogen atom or lower alkyl group, and -COOR substitutes for an ortho position or metha position of binding position of ring W] or a pharmaceutically acceptable salt thereof.

  本发明涉及作为人过氧化物酶体增殖激活受体（PPAR）激动剂，特别是作为人PPARα同工酶的激动剂，对脂质代谢异常、糖尿病等治疗有效的环氨基苯甲酸衍生物及其加成盐，以及含有这些化合物的药物组合物。 由通式（1）代表的环氨基苯甲酸衍生物 [其中，环 Ar 代表芳基，可具有取代基等；Y 代表 C1-C4 亚烷基、C2-C4 亚烯基、C2-C4 亚炔基等；Z 代表氧原子、硫原子或 - (CH2)n- （n 代表 0、1 或 2）；X 代表氢原子、卤素原子、可被卤素原子取代的低级烷基或类似物；R 代表氢原子或低级烷基，-COOR 取代环 W 结合位的正位或甲位]或其药学上可接受的盐。
• Diversifying Vancomycin via Chemoenzymatic Strategies
  作者：Xun Fu、Christoph Albermann、Changsheng Zhang、Jon S. Thorson

  DOI：10.1021/ol0501626

  日期：2005.4.14

  [GRAPHICS]The rapid diversification of glycopeptides via glycorandomization reveals that significantly diverse substitutions are tolerated and suggests there may be a synergistic benefit to the construction of mechanistically related natural product core scaffold fusions. This work also further highlights the utility of chemoenzymatic approaches to diversify complex natural product architectures.